OpenAI acquires Orchestra Bio for drug development
The Decoder: OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research. The article OpenAI acquires Orchestra Bio to build AI agents that speed up drug development appeared first on
Part of a story that several outlets report: OpenAI acquires Orchestra Bio for drug development
Get smart on it
OpenAI acquired a startup that coordinates drug development work and is integrating it into its life sciences AI platform to build AI agents that can link scientific findings with clinical trials and speed up the path to getting new drugs to patients. Drug development in the US typically takes ten to 15 years, with delays caused not only by scientific challenges but also by siloed systems and communication friction between internal teams and external partners. The acquired company's agents are designed to automate tasks like tracking trials, alerting teams when problems occur such as failed production batches, and suggesting next steps, which could allow scientists to focus on research decisions rather than coordination work. OpenAI already collaborates with other pharmaceutical companies on AI-driven drug research.
Relevant courses
Want to go deeper than the news? Explore live, cohort-based AI courses taught by practitioners.
Browse AI courses on MavenRelated news
Anthropic officially files for its public debut
Anthropic has officially filed for an IPO, revealing soaring revenue, mounting losses, major enterprise adoption, and an unusual governance structure designed to preserve founder control and its AI safety mission.
Also reported by SiliconANGLE, Wired AI and Crunchbase News
OpenAI working on new $30B raise at $1.25T valuation ahead of IPO
Should OpenAI command an over $1 trillion valuation with this round, it would break records as the most highly valued private company ever.
Also reported by SiliconANGLE and The Decoder
Anthropic’s IPO filing lays out a plan to ‘revolutionize every area of human endeavor’ with AI
Anthropic has filed its S-1 prospectus with the Securities and Exchange Commission, preparing the company behind Claude to beat OpenAI to the punch with an IPO. In a filing with the SEC, Anthropic said it plans to list on the Nasdaq exchange under the ticker symbol "ANT." The AI company confidentially filed with the SEC earlier this year in June, but the public document reveals more details, as well as the company's plans for the future in its own words, as well as potential r
Also reported by Wired AI
Bedrock Robotics nears $1B in total funding as demand for autonomous heavy equipment surges
Bedrock Robotics automates large excavators to improve construction site economics. | Credit: Bedrock Robotics San Francisco-based Bedrock Robotics has raised $600 million in Series C funding, co-led by CapitalG and Emergence Capital, at a $4.1 billion valuation. The round brings its total funding to nearly $1 billion as it scales fully autonomous heavy equipment to address nationwide construction labor shortages. The round included new investors US Innovative Technology Fund (USIT), Bessemer Ve
Five weird details from Anthropic’s IPO filing
Anthropic has finally filed its S-1 prospectus with the SEC, a document designed to give investors a look under the hood of its business, from how much its executives are making and plans for spending its IPO billions to the risks that could derail its ambitions. At more than 300 pages, there's a lot to unpack, and some of the disclosures have not previously been reported. Here are some of the biggest things that jumped out to us from our first pass: It pays to be an Amodei Sib
DeepSeek reportedly raises $15B days after US restrictions
DeepSeek has reportedly raised $15 billion in one of China's largest funding rounds, just days after the US ordered federal agencies to remove its technology over national security concerns.